Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$8.95 USD
+0.16 (1.82%)
Updated May 16, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
CNTA 8.95 +0.16(1.82%)
Will CNTA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CNTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNTA
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
CNTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
Other News for CNTA
Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)
Centessa’s Drug Development Hurdles: FDA Fast Track No Guarantee for Hemophilia B Treatment Approval
Groundbreaking Data Collection Platform opens to accelerate research in Central Disorders of Hypersomnolence
Buy Rating on Centessa Pharmaceuticals Based on Strong Pipeline and Financial Health
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024